Efficacy and safety of transarterial chemoembolization plus donafenib with or without camrelizumab for unresectable hepatocellular carcinoma: a propensity score matching analysis.

Front Immunol · 2026 · PMC13128621 · PMID 42079632

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, in the BCLC C subgroup, although the TACE+D+C group exhibited numerically longer mOS (11.7 months vs 10.00 months; P = 0.053) and mPFS (8.80 months vs 7.60 months; P = 0.078) compared with the TACE+D group, the differences did not reach statistical significance ( Figure 10B, D ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.